CCM
TNYA icon

CAAS Capital Management’s Tenaya Therapeutics TNYA Stock Holding History

CAAS Capital Management’s Portfolio TNYA Stock Details TNYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-50,000
Closed -$1.03M – 1048
2021
Q3 		$1.03M Buy
+50,000
New +$1.07M 0.02% 475

Other funds holding TNYA

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

CAAS Capital Management's TNYA Position: Q4 2021 in Review

CAAS Capital Management sold out of Tenaya Therapeutics (TNYA) in Q4 2021, closing a stake of 50,000 shares — an estimated $1.03M sold.

CAAS Capital Management first reported a position in TNYA in Q3 2021 and held it in 1 quarter. The position peaked at $1.03M in Q3 2021. 47 funds tracked by Wall St. Rank hold TNYA as of Q4 2021.

  • CAAS Capital Management reported no remaining Tenaya Therapeutics position as of Q4 2021 after selling out during the quarter.
  • CAAS Capital Management sold 50,000 Tenaya Therapeutics shares in Q4 2021, an estimated $1.03M.
  • CAAS Capital Management first reported a position in Tenaya Therapeutics in Q3 2021 and held it in 1 quarter.
  • CAAS Capital Management's Tenaya Therapeutics position peaked at $1.03M in Q3 2021.
  • 47 funds tracked by Wall St. Rank held Tenaya Therapeutics as of Q4 2021.

Based on CAAS Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.